<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00603980</url>
  </required_header>
  <id_info>
    <org_study_id>AMDC-002-102</org_study_id>
    <secondary_id>22 January 2008</secondary_id>
    <nct_id>NCT00603980</nct_id>
  </id_info>
  <brief_title>Abuse Liability of Staccato Alprazolam</brief_title>
  <official_title>Abuse Liability Study of StaccatoÂ® Alprazolam for Inhalation in Subjects With Histories of Sedative Abuse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexza Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexza Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compare the abuse liabilities of Staccato Alprazolam, oral immediate-release alprazolam, and
      Staccato Placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison to placebo and active controls for the categorical response to the question &quot;Rate the degree to which you would like to take the drug again&quot;</measure>
    <time_frame>End of day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison to placebo and active controls for the categorical response to the question &quot;Rate the overall STRENGTH and overall LIKING of the drug effect you experienced&quot;</measure>
    <time_frame>End of day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison to placebo and active controls for the percent of subjects reporting treatment emergent adverse events</measure>
    <time_frame>8 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Abuse Liability of Staccato Alprazolam</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Middle dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Middle dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Double placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alprazolam</intervention_name>
    <description>Staccato Alprazolam, single dose</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alprazolam</intervention_name>
    <description>oral, immediate release</description>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
    <arm_group_label>6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Staccato placebo + oral placebo</description>
    <arm_group_label>7</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects between the ages of 18 to 55 years, inclusive, who have a
             history of substance abuse or dependence on barbiturates and/or benzodiazepine
             receptor agonists for their intoxicating effects

        Exclusion Criteria:

          -  Subjects with a significant current psychiatric illness or taking any psychotropic
             prescription medications for therapeutic uses.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roland R Griffiths, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins University School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2008</study_first_submitted>
  <study_first_submitted_qc>January 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2008</study_first_posted>
  <last_update_submitted>March 20, 2009</last_update_submitted>
  <last_update_submitted_qc>March 20, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2009</last_update_posted>
  <responsible_party>
    <name_title>Daniel A. Spyker, MD / Sr Director, Drug Safety &amp; Pharmacovigilance</name_title>
    <organization>Alexza Pharmaceuticals, Inc</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alprazolam</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>March 12, 2017</submitted>
    <returned>April 26, 2017</returned>
    <submitted>June 16, 2017</submitted>
    <returned>January 25, 2018</returned>
    <submitted>January 29, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

